- Home
- CELZ vs PCSA Comparison
CELZ vs PCSA Comparison
Compare CELZ & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELZ
- PCSA
- Stock Information
- Founded
- CELZ 1998
- PCSA 2011
- Country
- CELZ United States
- PCSA United States
- Employees
- CELZ N/A
- PCSA N/A
- Industry
- CELZ Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- CELZ Health Care
- PCSA Health Care
- Exchange
- CELZ Nasdaq
- PCSA Nasdaq
- Market Cap
- CELZ 6.0M
- PCSA 4.5M
- IPO Year
- CELZ N/A
- PCSA N/A
- Fundamental
- Price
- CELZ $4.15
- PCSA $1.32
- Analyst Decision
- CELZ
- PCSA Buy
- Analyst Count
- CELZ 0
- PCSA 3
- Target Price
- CELZ N/A
- PCSA $5.00
- AVG Volume (30 Days)
- CELZ 35.5K
- PCSA 152.4K
- Earning Date
- CELZ 11-12-2024
- PCSA 11-11-2024
- Dividend Yield
- CELZ N/A
- PCSA N/A
- EPS Growth
- CELZ N/A
- PCSA N/A
- EPS
- CELZ N/A
- PCSA N/A
- Revenue
- CELZ $17,000.00
- PCSA N/A
- Revenue This Year
- CELZ N/A
- PCSA N/A
- Revenue Next Year
- CELZ N/A
- PCSA N/A
- P/E Ratio
- CELZ N/A
- PCSA N/A
- Revenue Growth
- CELZ N/A
- PCSA N/A
- 52 Week Low
- CELZ $2.65
- PCSA $1.19
- 52 Week High
- CELZ $10.28
- PCSA $17.40
- Technical
- Relative Strength Index (RSI)
- CELZ 57.21
- PCSA 49.37
- Support Level
- CELZ $2.78
- PCSA $1.21
- Resistance Level
- CELZ $5.58
- PCSA $1.29
- Average True Range (ATR)
- CELZ 0.49
- PCSA 0.08
- MACD
- CELZ 0.16
- PCSA 0.01
- Stochastic Oscillator
- CELZ 48.75
- PCSA 62.50
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).